SINOVAC BIOTECH LTD SVA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.83

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $386.0M$361.4M$470.2M$1.47B$19.37B$510.6M$246.1M$229.7M$174.3M$72.4M
Cost of revenue $124.0M$140.7M$146.9M$658.2M$988.9M$67.2M$32.5M$24.7M$20.2M$22.4M
Gross profit $262.0M$220.7M$323.3M$815.2M$18.38B$443.4M$213.6M$204.9M$154.1M$50.0M
R&D $216.2M$270.7M$350.2M$478.7M$152.7M$48.8M$24.3M$21.9M$20.5M$12.6M
SG&A $333.0M$420.9M$598.2M$836.1M$602.1M$176.5M$121.5M$137.0M$87.4M$42.0M
Total operating expenses $752.1M$726.2M$1.04B$1.32B$758.1M$227.8M$145.0M$159.6M$108.7M$49.5M
Operating income -$490.1M-$505.5M-$714.0M-$509.0M$17.62B$215.6M$68.6M$45.3M$45.4M$504.0K
Pre-tax income -$262.1M$42.8M-$84.5M-$48.5M$17.57B$216.6M$70.8M$46.6M$45.0M-$394.0K
Income tax $63.3M$2.2M$36.4M$11.5M$3.45B$31.4M$5.6M$10.5M$8.3M$2.7M
Net income -$198.8M$40.7M-$120.9M$14.5M$8.12B$110.4M$44.9M$21.8M$25.8M-$596.0K
EPS, basic -0.831.27-0.190.20113.541.060.420.340.45-0.01
EPS, diluted -0.831.27-0.190.20113.440.970.410.340.45-0.01
Shares, diluted (wtd. avg.) 71.9M71.9M71.9M71.8M71.6M113.7M109.7M65.0M57.1M56.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $488.2M$335.3M$1.13B$3.89B$11.61B$1.05B$155.9M$158.2M$116.0M$65.4M
Short-term investments $5.48B$9.61B$9.89B$6.65B$1.81B$135.2M$50.3M$18.9M——
Receivables $286.3M$300.9M$424.9M$486.6M$942.7M$253.5M$113.7M$74.5M$66.2M$49.8M
Inventory $94.3M$96.9M$135.6M$175.3M$391.1M$105.8M$27.8M$25.1M$19.6M$14.1M
Total current assets $7.06B$10.64B$11.60B$11.30B$14.94B$1.56B$349.6M$284.2M$203.9M$130.7M
Property, plant and equipment $706.1M$881.0M$952.0M$989.7M$855.0M$200.4M$74.3M$70.9M$76.4M$66.9M
Goodwill $12.6M$27.5M$0$0$0—————
Other intangibles $77.7M$122.6M$8.5M$9.7M$1.5M$1.5M————
Total assets $8.54B$12.34B$13.61B$14.03B$16.76B$1.90B$452.3M$369.8M$299.2M$211.4M
Accounts payable $604.7M$803.0M$989.2M$924.7M$1.03B$211.4M$58.9M$50.0M$59.4M$25.0M
Short-term debt ———————$3.3M$18.2M$31.3M
Total current liabilities $1.54B$1.45B$1.29B$1.26B$2.52B$679.6M$87.2M$58.2M$92.5M$66.3M
Long-term debt $494.9M$375.8M$253.9M$11.8M$15.8M$35.1M$5.9M$7.2M$33.0M$40.7M
Total liabilities $2.15B$2.04B$1.97B$1.79B$3.21B$781.2M$100.1M$77.9M$122.1M$81.7M
Retained earnings $2.82B$6.84B$6.79B$6.80B$6.81B$144.2M$56.7M$23.8M$9.1M-$11.9M
Total equity $4.44B$8.26B$11.64B$12.24B$9.00B$1.13B$352.2M$291.9M$177.1M$129.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$512.2M-$56.9M$138.6M-$798.1M$15.32B$479.3M$39.1M$7.9M$59.8M-$13.9M
Depreciation and amortisation $97.4M$110.2M$157.4M$152.7M$85.1M$3.7M$4.6M$4.9M$4.6M$5.1M
Stock-based compensation —$0$0$0$7.7M$10.2M$3.0M$4.3M$979.0K$2.4M
Capital expenditure $48.9M$96.0M$156.2M$313.9M$594.2M$0$10.6M$5.6M$11.9M$12.7M
Investing cash flow $4.39B$456.4M-$2.70B-$6.09B-$2.98B-$204.8M-$42.5M-$25.3M-$11.9M-$11.8M
Financing cash flow -$3.43B-$824.0M-$88.6M-$299.5M-$1.91B$592.6M$1.7M$64.2M-$1.3M$27.8M
Dividends paid $3.53B$947.0M$328.1M$247.4M$1.88B$0$0———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-258534.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -5B 0 5B 10B 15B 20B Revenue, FY2016: 72.4M Gross profit, FY2016: 50M Net income, FY2016: -596K Revenue, FY2017: 174.3M Gross profit, FY2017: 154.1M Net income, FY2017: 25.8M Revenue, FY2018: 229.7M Gross profit, FY2018: 204.9M Net income, FY2018: 21.8M Revenue, FY2019: 246.1M Gross profit, FY2019: 213.6M Net income, FY2019: 44.9M Revenue, FY2020: 510.6M Gross profit, FY2020: 443.4M Net income, FY2020: 110.4M Revenue, FY2021: 19.4B Gross profit, FY2021: 18.4B Net income, FY2021: 8.1B Revenue, FY2022: 1.5B Gross profit, FY2022: 815.2M Net income, FY2022: 14.5M Revenue, FY2023: 470.2M Gross profit, FY2023: 323.3M Net income, FY2023: -120.9M Revenue, FY2024: 361.4M Gross profit, FY2024: 220.7M Net income, FY2024: 40.7M Revenue, FY2025: 386M Gross profit, FY2025: 262M Net income, FY2025: -198.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $72.4M $174.3M $229.7M $246.1M $510.6M $19.37B $1.47B $470.2M $361.4M $386.0M
Gross profit $50.0M $154.1M $204.9M $213.6M $443.4M $18.38B $815.2M $323.3M $220.7M $262.0M
Net income -$596.0K $25.8M $21.8M $44.9M $110.4M $8.12B $14.5M -$120.9M $40.7M -$198.8M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%